- Author: Kathy Keatley Garvey
Casida, 88, one of the world's leading authority on how pesticides work and their effect on humans, died June 30 of a heart attack in his sleep at his home in Berkeley. He was considered the most preeminent pesticide toxicologist over at least the last two centuries.
A distinguished professor emeritus of environmental science, policy and management and of nutritional sciences and toxicology, Casida was the founding director of the campus's Environmental Chemistry and Toxicology Laboratory.
When awarded the Wolf Prize in Agriculture in 1993, the Wolf Foundation lauded his “research on the mode of action of insecticides as a basis for the evaluation of the risks and benefits of pesticides and toxicants, essential to the development of safer, more effective pesticides for agricultural use." according to a UC Berkeley News Service story. "His discoveries span much of the history of organic pesticides and account for several of the fundamental breakthroughs in the fields of entomology, neurobiology, toxicology and biochemistry.”
Former graduate student Bruce Hammock, now a distinguished professor at the University of California, Davis, who holds a joint appointment with the UC Davis Department of Entomology and Nematology and the UC Davis Comprehensive Cancer Center, remembers him as a “lifelong mentor who evolved into a colleague and a friend.”
“John continued his high productivity until his death with major reviews on pesticides in 2016, 2017, and 2018 in addition to numerous primary papers,” Hammock noted. “He was working on primary publications as well as revising his toxicology course for the fall semester at the time of his death. Pesticide science was the theme of his career, and we live in a world with far safer and more effective pest control agents because of his effort.”
John Casida opened multiple new fields ranging from fundamental cell biology through pharmaceutical discovery. "He pioneered new technologies throughout his career, from being one of the first to use radioactive compounds for pesticide metabolism through studies with accelerator mass spectrometry, photoaffinity labeling and others," Hammock related. "Yet the greatest impact of his career probably lives on in the numerous scientists he trained, now carrying on his traditions of excellence in science. These scientists are around the world in governmental, industrial and academic careers.”
As compiled and shared by Hammock, below are comments from a few of his doctoral students and postdoctoral fellows who worked both with Casida at UC Berkeley and at, least for a time, also were at UC Davis.
Sarjeet Gill
Distinguished Professor of Cell Biology and Neuroscience, University of California, Riverside
"This project also allowed me to build a long lasting friendship with Bruce Hammock who also was on the same project. Since John was always very focused, I often challenged John's patience with my practical jokes. I am sure he knew who the culprit(s) were but he never revealed he knew.
“The research experiences in John's lab made an indelible impression on me that drove me to return to the United States from Malaysia for an academic career in the UC system. Personally, I have lost an incredible mentor, and the scientific community lost the most preeminent pesticide toxicologist in the last two centuries. John changed the way we investigated mechanisms of toxicity at all levels. I certainly will miss him dearly.
Bruce Hammock
Distinguished Professor at the University of California, Davis: Joint appointment with the Department of Entomology and Nematology and the UC Davis Comprehensive Cancer Center
"After telling him I was there to be his graduate student, he replied he had no money for students. My retort was that I had a fellowship. He then told me that students were not space effective, and I promised not to take up much space. He continued that students were not time effective, and I promised not to take his time. In retrospect, Sarjeet must have really soured him on graduate students a few hours earlier."
"Months later, Sarjeet and I were sharing a desk-lab bench in the windowless closet next to the 'fly room' when Dr. Casida walked in. He had noted we both listed him as our major professor and asked if there was anything, he could do to encourage us to leave. When in unison we replied 'No!,' he politely left without accepting us, but soon we both had a desk and bench.
"So a few paces after Sarjeet, I initiated the most thrilling four years of my life. John's introduction to experimental science was marvelous with the perfect balance of inspiration, instruction and tremendous freedom. I was privileged to learn from a wonderful group of individuals and, of course, I made my most enduring of friendships with Sarjeet Gill. In addition to science, John taught a life-family-science balance by example. John was my life long mentor in science and in life but also evolved as a colleague and friend.
"Three more delightful years passed and John then took me to lunch at the faculty club. As I was about to leave the laboratory for the U.S. Army, he gave me sagely advice such as he had had it easy during the Sputnik period and I would have it hard. Then he went on to tell me than most people in the laboratory did not find my practical jokes nearly as funny as I did. I did not reveal that Sarjeet had both planned and executed most of them. Thus, Sarjeet succeeded in disrupting my Berkeley career from beginning until the end.
"John and his laboratory at Berkeley provided me with the most exciting years of my scientific career. In his own work, John moved from strength to strength creating numerous entire fields along the way. His scientific insight and drive were a constant stimulation to drive for innovation and excellence. Whenever I had an opportunity, I encouraged others to join his team. John was an inspiration and role model, not only because John came in early and stayed late, but also because he did science for the fun of discovery and taught for the joy of teaching."
Keith Wing Consulting LLC
Life Science Industrial Biochemistry or Biotechnology
"While we all worked hard including many evenings and weekends, there were times when I or other American rebels would lead a mass lab exodus for a salmon fishing or ski trip during (gasp!) regular business hours. John would pretend to barely notice our ill-disguised escape along the cabinets that lined the Wellman Hall basement, except to raise his right eye from his manuscript editing in an unmistakable sign of disapproval at our lack of scientific drive.
"And this leads to another Casida work pattern of the time…. All of us scientists were subject to John's multiple cycles of manuscript editing. We would wrack our brains trying to put the right words and figures down as manuscript drafts, submit them to John, and wait for three days or less for him to return it to us in a sea of thin red ink, and the humbling realization that we really were much poorer writers than we'd thought. After discussion with John and acquiescing to practically every edit he'd made, the manuscript would be re-typed manually by his administrative assistants in entirety and the cycle would repeat but with less red ink. After at least three cycles of this, we'd submit the manuscript for publication, often with a high acceptance rate. With time, we all came to understand and see John's wisdom in approaching publication and science contribution. All of this occurred right as word processing programs had started taking hold in the outside world, and perhaps my one service to the lab on my 1983 exit was to convince John to look into using word processing/saving documents on disks for editing. Oh, and maybe a bit of science as well.
"John Casida's lab has been the world leader in examining both pesticide metabolism and their biochemical target sites. I was lucky enough to work on a project that combined both, and it molded the way I looked at insecticide discovery in industry. The interdisciplinary approach to the mechanisms by which xenobiotics interface with biological systems influenced the thinking of every person who has passed through John's lab. That influence has proliferated throughout the world and has advanced the field of pesticide toxicology to what it is today. We mourn the loss of a great leader but understand that his alumni are a large international family that will carry his spirit and teachings forward."
Andrew 'Andy' Waterhouse
Director of the Robert Mondavi Institute for Wine and Food Science and Professor of Viticulture and Enology,
University of California, Davis
"A couple of weeks after I arrived, he showed me Don Crosby's book on natural toxicants, and asked if I would confirm the very high toxicity of ryanodine mentioned therein. The high toxicity suggested strong binding to a key regulatory protein, and its novel and unknown mode of action made it an exciting prospective target. Confirming that ryanodine was in fact a deadly toxic, he set a project in motion to discover the site of action, hiring Isaac Pessah to use the yet-to-be-made radioligand on a hypothetical site of action!
"We were astonishingly lucky to find that the natural source of ryanodine contained a major impurity that was one step away from the highly radioactive form, so it wasn't too long before we had very hot ryanodine available. Initial attempts detected no binding at all, but Isaac thought to add some calcium to the assay, and we had the binding site in hand! This discovery essentially established a field of science in muscle physiology and pharmacology, with entire symposia dedicated to exploring this binding site and its broader significance to toxic modes of action. Isaac is an established leader in the field. It was a real privilege to see how groundbreaking research can happen and be part of it, and to get to know all the fabulous scientists that John collected around him."
Isaac Pessah
Associate Dean of Research and Graduate Education, and Professor, Department of Molecular Biosciences, UC Davis School of Veterinary Medicine
University of California, Davis
"I remember most vividly my reaction when John also indicated that working on the biochemistry GABA receptors, my original intent for traveling across country for a postdoc, was not to be. ‘Work on something else' John advised, ‘there are so many interesting unanswered questions around the PCTL.' Arguably John's straightforward and highly insightful advice changed the course of my professional life. He introduced me to chemist Andy Waterhouse, and the next two years of work that led to the discovery and identity of the ryanodine receptor were breathtaking. Our discovery benefited from many factors; a gift from Ryania speciosa in the form of didehydroryanodine, which Andy identified, the newly published use of palladium catalyst to catalyze efficient reduction of minute quantities of unsaturated bonds, the National Tritium Laboratory just above the PCTL…and of course, there was John's unwavering support for discovery, no matter how risky. Successful synthesis of [3H]ryanodine and identity of its receptor paved the way to immense basic discoveries in virtually every field of science, identification of several disease causing mutations of skeletal and cardiac muscle and the nervous system, and successful discovery of highly selective ryanoid insecticides. Since the first paper published in 1985, there have been nearly 20,000 peer reviewed publications (ISI Web of Science) and a search on Google Scholar yields more than 70,000 hits. To many, John was the recognized leader in pesticide chemistry and toxicology. I agree, although from my perspective, John was also a true renaissance individual, seeding ideas of great significance in so many fields, of which ryanodine receptors represents only one of many. His love of science and discovery positively impacted his students and postdocs. He will be fondly remembered and sorely missed.'
Qing Li
Professor, Department of Molecular Biosciences and Bioengineering College of Tropical Agriculture and Human Resources, University of Hawai‘i at Mānoa 
" In April 2018, I had a couple of telephone conversations with Professor Casida. He shared with me what he was doing (of course, writing manuscripts), his health, Kati's health, his sons and his grandkids. We talked about meeting at the Biochemistry and Society: Celebrating the Career of Professor Bruce Hammock, to be held in Davis in August 2018. We talked about a possibility to attend a meeting together in China in 2019.
"I was privileged to manage Professor Casida's manuscript entitled 'Pesticide Detox by Design' that he submitted to the Journal of Agricultural and Food Chemistry. This is Professor Casida's last manuscript, I believe. It is still in the review process. He wrote that 'Detoxification (detox) plays a major role in pesticide action and resistance…' A reviewer who reviewed the manuscript wrote me “I just heard that Professor Casida has passed away... Professor Casida was a giant in pesticide science, a special and unique person. It is a great loss to the pesticide science community…”
Professor Casida is survived by his wife, artist and sculptor Kati Casida, sons Mark and Eric Casida, and two grandchildren.
Related Information
- John Casida Obituary, UC Berkeley News Service
- For the Fun of Science: A Discussion with John E. Casida (Archives of Insect Biochemistry and Physiology)
- Still Curious: An Overview of John Casida's Contributions to Agrochemical Research (JAFC)
- Curious about Pesticide Action, by John E. Casida (JAFC)
- Author: Kathy Keatley Garvey
Water balloons, water guns, super sprayers, and buckets prevailed when dozens of scientists participated in the 15th annual Bruce Hammock Lab Water Balloon Battle on the Briggs Hall lawn at the University of California, Davis.
The July event, also known as "Bruce's Big Balloon Battle at Briggs," proved to be an international soakfest. That's because the 28 researchers in the Hammock lab hail from seven countries: the United Stares, China, France, Ukraine, Lebanon, Japan and Korea. They include postdoctoral scholars, researchers, graduate students, visiting scholars, visiting graduate students, visiting summer students, short-term visiting scholars and student interns.
The annual battle amounts to 15 minutes, or "15 Minutes of Aim." That's how long it takes for the some 40 water warriors to toss 2,000 water balloons. Joining in were scientists from the Aldrin Gomes lab, UC Davis Department of Neurobiology, Physiology and Behavior; Frank Zalom lab of the UC Davis Department of Entomology and Nematology; and the UC Davis Department of Mathematics, plus family and friends.
Hammock, a UC Davis distinguished professor who holds a joint appointment with the UC Davis Department of Entomology and the UC Davis Comprehensive Cancer Center, hosts the annual event in mid-July when triple-digit temperatures strike the campus. It's an opportunity for the lab members--who work hard throughout the year and play hard for 15 minutes--to engage in a little fun and camaraderie. The thirsty lawn benefits, too.
First the water warriors fill the balloons in an assemblyline procedure, and at exactly 3 p.m., the soakfest begins. As the H2O dwindles, they empty buckets at unsuspecting targets. The last part: picking up every single balloon remnant from the lawn.
Hammock, trained as a entomologist, chemist and toxicologist--and who now focuses his research on human health, is recognized for his work on using natural chemical mediators to control inflammation and intractable pain. He co-discovered the soluble epoxide hydrolase, and many of his more than 1100 publications and patents are on the P450 branch of the arachidonate cascade where the soluble epoxide hydrolase (sEH) degrades natural analgesic and anti-inflammatory compounds.
Hammock, an alumnus of UC Berkeley with a doctorate in entomology, joined the UC Davis faculty in 1980. He is the founding director (1987-present) of the UC Davis NIEHS (National Institute of Environmental Health Sciences) Superfund Research Program and is a founding member (1990-present) of the UC Davis Comprehensive Cancer Center. He has directed the UC Davis NIH/NIEHS Combined Analytical Laboratory for 25 years.
Highly honored by his peers, Hammock is a fellow of the National Academy of Inventors, which honors academic invention and encourages translations of inventions to benefit society. He is a member of the U.S. National Academy of Sciences, a fellow of the Entomological Society of America, and the recipient of the Bernard B. Brodie Award in Drug Metabolism, sponsored by the America Society for Pharmacology and Experimental Therapeutics. He is the first McGiff Memorial Awardee in Lipid Biochemistry. The Eicosanoid Research Foundation recently honored him for work on oxidized lipids.
But on one day in July--for 15 minutes--noted academician Bruce Hammock leaves his Briggs Hall office and transforms into an elite water warrior. He's practiced for 15 years, 15 minutes at a time.
"Bruce has a good aim," said Christophe Morisseau, a Hammock lab researcher who coordinates the annual battles.
- Author: Kathy Keatley Garvey
The paper, which indicates that a brain enzyme could play a key role in curbing or preventing the progression of Parkinson's disease, is one of four singled out as exemplary on the NIEHS website.
“This could be a “revolutionary paper that could cure Parkinson's disease,” commented co-author Bruce Hammock, a UC Davis distinguished professor of entomology with a joint appointment with the UC Davis Comprehensive Cancer Center. He is the 30-year director of the UC Davis NIEHS Superfund Program, which helped fund the research. "A related compound to the drug used in the paper will enter human safety trials sponsored by NIH in early 2019."
The team of 14 scientists demonstrated that inhibiting the enzyme soluble epoxide hydrolase (sEH) compound in mice helped curb the inflammation associated with the development and progression of Parkinson's disease (PD), an age-related brain disorder that affects a million Americans, mostly 60 and over.
The researchers exposed mice to methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP), a neurotoxicant that leads to symptoms of PD in animals. They found two approaches that protected against MPTP-induced neurotoxicity in the mouse brain--adding a potent sEH inhibitor, and genetically modifying mice to not produce sEH.
“Our research suggests that the sEH inhibitor may prevent the progression of Parkinson's disease (PD) as well as treat patients with dementia of Lewy bodies (DLB) if the sEH inhibitor is used in early phases of patients with these disorders,” said Hashimoto, whose career spans 30 years in the development of blood biomarkers and novel therapeutic drugs and includes more than 550 publications on the topic. “Both PD and DLB are chronic and progressive movement disorders. However, the precise causes of these diseases are largely unknown.” Lead author was Qian Ren of the Hashimoto lab.
Hammock and a colleague Sarjeet Gill (now of UC Riverside) discovered the sEH enzyme in a UC Berkeley lab while they were researching insect developmental biology and green insecticides. The work, begun in 1969, led to the discovery that many regulatory molecules are controlled as much by degradation as by biosynthesis, Hammock said. These epoxy fatty acid chemical mediators control blood pressure, fibrosis, immunity, tissue growth, and pain and inflammation.
The Hammock laboratory has published nearly 900 peer-reviewed papers on the sEH enzyme. To date, journals have published more than 17,000 peer-reviewed papers on the sEH enzyme and its inhibitors. Hammock credits the NIEHS with supporting his research in this area since the 1970s.
A Davis-based company, EicOsis, is developing inhibitors to sEH to treat unmet medical needs in humans and animals. The company recently received a multi-million dollar grant from the NIH/NINDS Blueprint Program to move sEH inhibitors through phase I human clinical trials. "We are developing a non-opiate analgesic to treat the chronic pain often associated with diabetes,” said William Schmidt, vice president of clinical development at EicOsis. “Once we have investigational new drug status from the Food and Drug Administration and have finished our phase I trial, physicians will be able initiate their own trials with the EicOsis compound on Parkinson's disease and other Lewy body disorders.”
Hammock said the soluble epoxide hydrolase inhibitors that inhibit the soluble epoxide hydrolase will soon enter human clinical trials supported by the NIH-NINDS Blueprint Program (NIH's Health's National Institute of Neurological Disorders and Stroke). “These drugs could provide relief for patients with a wide variety of inflammatory diseases,” said Hammock, who is a member of the National Academy of Sciences and the National Academy of Inventors.
Resources:
- See initial news story on UC Davis Department of Entomology and Nematology website
- See PNAS paper
- Author: Kathy Keatley Garvey
Hammock will present a plenary lecture on Thursday, May 31, offering an overview of the current state of the science in the area of oxidized lipids.
ISSFAL is “the leading showcase of what is new, exciting, and interesting in science and research in this field,” said executive committee member and organizing committee chair Hee Yong Kim, who serves as chief of the laboratory of Molecular Signalling for the National Institute of Health's National Institute on Alcohol Abuse and Alcoholism (NIH/NIAAA).
Hammock is known for his work on using natural chemical mediators to control inflammation and intractable pain. He continues as the founding director of the campuswide Superfund Research Program--this is the 31st year--and the NIH's National Institute of Environmental Health Sciences (NIEHS) Combined Analytical Laboratory. He has directed the NIH/ NIEHS Combined Analytical Laboratory for 25 years.
Hammock co-discovered the soluble epoxide hydrolase, and many of his more than 1100 publications and patents are on the P450 branch of the arachidonate cascade where the soluble epoxide hydrolase degrades natural analgesic and anti - inflammatory compounds. The founder of several companies, he has helped raise more than $50 million in private capital, and currently is chief executive officer of the Davis-based EicOsis, where an orally active non- addictive drug for inflammatory and neuropathic pain is being developed for human beings companion animals. EicOsis is supported by several seed-fund grants and a NIH/NINDS (National Institute of Neurological Disorders and Stroke) Blueprint Development Grant.
Highly honored by his peers, Hammock is a fellow of the National Academy of Inventors, which honors academic invention and encourages translations of inventions to benefit society. He is a member of the U.S. National Academy of Sciences, a fellow of the Entomological Society of America, and the recipient of the Bernard B. Brodie Award in Drug Metabolism, sponsored by the America Society for Pharmacology and Experimental Therapeutics. He is the first McGiff Memorial Awardee in Lipid Biochemistry.
The Eicosanoid Research Foundation recently honored him for work on oxidized lipids. (See more on his website)
- Author: Kathy Keatley Garvey
A newly published study by a team of scientists at Chiba University, Japan and at the University of California, Davis shows that inhibiting an enzyme, the soluble epoxide hydrolase (sEH), plays a key role in curbing the inflammation associated with the development and progression of Parkinson's disease, an age-related brain disorder that affects a million Americans, mostly 60 and over.
The research, published today in the Proceedings of the National Academy of Sciences, is primarily the work of scientists in the labs of Kenji Hashimoto, a professor with the Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan, and Bruce Hammock, UC Davis distinguished professor of entomology with a joint appointment in the UC Davis Comprehensive Cancer Center.
“Our research suggests that the sEH inhibitor may prevent the progression of Parkinson's disease (PD) as well as treat patients with dementia of Lewy bodies (DLB) if the sEH inhibitor is used in early phases of patients with these disorders,” said Hashimoto, whose career spans 30 years in the development of blood biomarkers and novel therapeutic drugs and includes more than 550 publications on the topic. “Both PD and DLB are chronic and progressive movement disorders. However, the precise causes of these diseases are largely unknown.”
Statistics indicate physicians diagnose 60,000 new cases of Parkinson's disease every year in the United States. The average age of onset is 60, and is more predominant among men.
Hammock said that the work by lead author Qian Ren and his colleagues in the Hashimoto lab “shows that markers and symptoms of Parkinson's disease in whole mice and in human cells with a mutation associated with Parkinson's disease can be treated with a small druglike molecule. By establishing this causal chain of events leading to Lewy body disorders we can better predict environmental chemicals that could predispose people to Parkinson's disease and possibly even treat the disease.”
The paper, titled “Soluble Epoxide Hydrolase Plays a Key Role in the Pathogenesis of Parkinson's Disease,” is co-authored by 14 scientists, including Professor Hammock and Jun Yang and Sung Hee Hwang, all part of the UC Davis Department of Entomology and Nematology and the UC Davis Comprehensive Cancer Center.
“Although there are many medications available to treat symptoms in PD, these do not prevent the progression of the disease, and, to date, no agent with a disease-modifying or neuroprotective indication for PD has been approved,” said Hashimoto. “Therefore, the development of new drugs possessing disease-modifying and /or neuroprotective properties is critical.”
In research studies involving mice, the scientists found “that sEH plays a key role in the inflammation associated with PD pathogenesis and the mechanisms that lead to the disease,” Hashimoto said. “The sEH inhibitor or deletion of the sEH gene protected against MPTP-induced neurotoxicity in mouse brain.” MPTP is an acronym for methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine, a relative of cyperquat and paraquat herbicides. “Our findings indicate that sEH inhibitors or epoxy fatty acids mimics may be promising prophylactic or therapeutic drugs for alpha-synuclein-related neurodegenerative disorders.”
Robert Higgins, emeritus professor of neuropathology at the UC Davis School of Veterinary Medicine, said: "I find it exciting that Ren and colleagues illustrate a promising path to a drug to prevent the progression of Parkinson's disease. It is impressive how far this work has come since we collaborated with Shirley Gee and the Hammock laboratory on developing a sheep model of Parkinson's disease in the early 1980s."
Neurosurgeon Cesar Borlongan of Morsani College of Medicine, University of South Florida, who was not involved in the study, praised the findings as advancing “our understanding of how Parkinson's disease evolves.” Describing Parkinson's disease as “a devastating brain disorder that mostly affects the aging population,” he said: “There is no cure, only relief from symptoms which include tremors, muscle rigidity, slurred speech, and freezing of gait.”
“While we know that a certain group of brain cells that produce dopamine are selectively destroyed in Parkinson's patients, what triggers this brain cell death remains poorly understood,” said Borlongan, a distinguished professor and vice chair for Research, Department of Neurosurgery and Brain Repair. “In their paper, the authors observed that a protein called soluble epoxide hydrolase (sEH) may be key to the demise of the brain dopamine cells. In small and large animal models of Parkinson's disease, and further confirmed in a group of PD patients, this protein is highly elevated in specific regions of the brain implicated in dopamine cell death.”
Borlongan pointed out that “Equally compelling evidence demonstrated that using a drug that inhibits sEH can reduce brain inflammation and levels of sEH and effectively lessen PD-associated toxicity in the animal models of the disease. Clinical trials of sEH inhibitors in heart and lung disease have been ongoing over the last decade, and may facilitate the entry of these drugs for PD. These results advance our understanding of how PD may evolve, but also point to its novel treatment.”
Qing Li, a professor in the Department of Molecular Biosciences and Bioengineering, College of Tropical Agriculture and Human Resources, University of Hawaii at Mānoa, who also was not involved in the study, called Parkinson's disease “a devastating neurodegenerative disorder that affects patients and caregivers alike with a significant economic burden in the United States and worldwide.”
This basic research drew support from several grants from Japan, including the Strategic Research Program for Brain Sciences, and at UC Davis, grants funded by the National Institute of Health's Institute of Environmental Health Sciences (NIH/NIEHS), and the NIEHS Superfund Program.
Hammock, a member of the National Academy of Sciences and the National Academy of Inventors, has directed the NIH/NIEH Superfund Program for more than 30 years.
Hammock said the soluble epoxide hydrolase inhibitors that inhibit the soluble epoxide hydrolase will soon enter human clinical trials supported by the NIH-NINDS Blueprint Program (NIH's Health's National Institute of Neurological Disorders and Stroke). “These drugs could provide relief for patients with a wide variety of inflammatory diseases,” he said.
The Hammock laboratory has published nearly 900 peer-reviewed papers on the sEH enzyme, discovered while Hammock and Sarjeet Gill (now of UC Riverside) were researching insect developmental biology and green insecticides at UC Berkeley. The work, begun in 1969, led to the discovery that many regulatory molecules are controlled as much by degradation as by biosynthesis, Hammock said. These epoxy fatty acid chemical mediators control blood pressure, fibrosis, immunity, tissue growth, and pain and inflammation.
To date, journals have published more than 17,000 peer-reviewed papers on the sEH enzyme and its inhibitors. Hammock credits the NIEHS for supporting his research in this area since the 1970s.
A Davis-based company, EicOsis, is developing inhibitors to sEH
to treat unmet medical needs in humans and animals. The company recently received a multi-million dollar grant from the NIH/NINDS Blueprint Program to move sEH inhibitors through phase I human clinical trials. “We are developing a non-opiate analgesic to treat the chronic pain often associated with diabetes,” said William Schmidt, vice president of clinical development at EicOsis. “Once we have investigational new drug status from the Food and Drug Administration and have finished our phase I trial, physicians will be able initiate their own trials with the EicOsis compound on Parkinson's disease and other Lewy body disorders.”
